

Patent
Attorney Docket No. 1034123-000170

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
Joseph L. Witztum et al.

Application No.: 10/552,330

Filing Date: October 11, 2005

Title: METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSIS

Group Art Unit: Unknown
Examiner: Unknown
Confirmation No.: Unknown

**FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- No additional fee for submission of an IDS is required.
- The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- Charge _____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of _____ is enclosed for the fee due.
- Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL LLP

By

Michael P. Reed

Registration No. 45,647

Date: January 17, 2006


I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: January 17, 2006

Kim A. Cabello
Typed Name:

(8/05)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **MAIL STOP: IDS**
Witztum et al.)
Application No.: 10/552,330) Group Art Unit: Unknown
Filed: October 11, 2005) Examiner: Unknown
For: METHODS AND COMPOSITIONS FOR) Confirmation No.: Unknown
TREATING ATHEROSCLEROSIS) Certificate of Mailing
I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail on January 17, 2006, in an envelope
addressed to the Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450
By: 
Kim A. Cabello

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date January 17, 2006

By: 
Michael P. Reed
Registration No. 45,647

12230 El Camino Real
Suite 300
San Diego, CA 92130-2090
(858) 509-7300

Substitute for form 1449A/PTO & 1449B/PTO				<i>Complete if Known</i>	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	10/552,330
				Filing Date	October 11, 2005
				First Named Inventor	Joseph L. Witztum
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	034123-000170

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Kearney, J. F., Immune Recognition of OxLDL in atherosclerosis, J. Clinical Investigation, June 2000, Vol. 105, No. 12, p. 1683-1685
	Shaw, P. X. et al., Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance and protective immunity, J. Clinical Investigation, June 2000, Vol. 105, No. 12, p. 1731 -1740

Examiner Signature _____ **Date Considered** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.